ArticleJournal of clinical medicine2020
Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Radiographic severity and treatment optimisation inERJ open research · 2026Article
- Current and emerging treatment strategies forEwha medical journal · 2025Review
- Article
- From anonymity to stardom: history of nontuberculous mycobacterial disease in humans.Frontiers in cellular and infection microbiology · 2025Review
- Review
- Treatment Outcomes of Clofazimine-Containing Regimens in SevereOpen forum infectious diseases · 2024Article
- In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.BMC microbiology · 2022Article
- Risk Factors for the Development of Nontuberculous Mycobacteria Pulmonary Disease during Long-Term Follow-Up after Lung Cancer Surgery.Diagnostics (Basel, Switzerland) · 2022Article
- Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity.Scientific reports · 2022Article
- In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.Journal of clinical medicine · 2021Article
- Treatment-RefractoryOpen respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited data are available regarding optimal treatment for refractory
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.